Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 1035Neoplasms 813Carcinoma, Non-Small-Cell Lung 796Prostatic Neoplasms 617Colorectal Neoplasms 533Lung Neoplasms 478Neoplasm Metastasis 434Multiple Myeloma 394Leukemia, Myeloid, Acute 380Ovarian Neoplasms 333Pancreatic Neoplasms 316Melanoma 293Squamous Cell Carcinoma of Head and Neck 266Recurrence 260Carcinoma, Hepatocellular 248Glioblastoma 237Brain Neoplasms 236Triple Negative Breast Neoplasms 213Head and Neck Neoplasms 210Carcinoma, Renal Cell 207Precursor Cell Lymphoblastic Leukemia-Lymphoma 203Lymphoma 198Stomach Neoplasms 197Endometrial Neoplasms 190Uterine Cervical Neoplasms 182Lymphoma, Non-Hodgkin 182Sarcoma 180Glioma 179Lymphoma, Large B-Cell, Diffuse 166Hematologic Neoplasms 162

Interventions

Gemcitabine 2Taxes 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Metastatic Pancreatic Ductal Adenocarcinoma × 90 days × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Akeso

Phase 1/2 Active not recruiting
110 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡